Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib

Int Med Case Rep J. 2020 Mar 16;13:89-93. doi: 10.2147/IMCRJ.S229080. eCollection 2020.


Background: Crizotinib is the first tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC). An increased incidence of renal cysts has been described during the crizotinib treatment.

Case presentation: We herein report the case of a 74-year-old woman who received crizotinib for metastatic ALK-positive NSCLC. During the crizotinib treatment, complex renal cystic lesions with invasion of perirenal spaces and iliopsoas muscle appeared; two complex hepatic cysts were also observed. Almost all lesions disappeared after switching to alectinib, a second-generation ALK inhibitor.

Conclusion: It would seem that alectinib is able to reduce in size and number hepatic and renal cysts caused by the crizotinib treatment. Nevertheless, further studies are needed to clarify the role of both crizotinib in the onset of renal and hepatic cysts and alectinib in their disappearance.

Keywords: alectinib; anaplastic lymphoma kinase; crizotinib; hepatic cysts; non-small-cell lung cancer; renal cysts.

Publication types

  • Case Reports